Similar articles

• Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?

  Dayer JM. Dayer JM. J Rheumatol Suppl. 2002 Sep;65:10-5. J Rheumatol Suppl. 2002. PMID: 12236616 Review.
• The Jak-STAT pathway in rheumatoid arthritis.

  Walker JG, Smith MD. Walker JG, et al. J Rheumatol. 2005 Sep;32(9):1650-3. J Rheumatol. 2005. PMID: 16142855 No abstract available.
• Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.

  Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Redlich K, et al. Arthritis Rheum. 2003 Dec;48(12):3308-19. doi: 10.1002/art.11358. Arthritis Rheum. 2003. PMID: 14673982 Review. No abstract available.
• [Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis].

  Sugiyama E. Sugiyama E. Clin Calcium. 2007 Apr;17(4):528-34. Clin Calcium. 2007. PMID: 17404481 Review. Japanese.
• [Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].

  Gabay C. Gabay C. Rev Med Suisse Romande. 2000 Jun;120(6):529-33. Rev Med Suisse Romande. 2000. PMID: 11014098 Review. French. No abstract available.